The myasthenia gravis (MG) condition is an autoimmune disorder that affects the membrane that surrounds the neuromuscular junction and is known as the postsynaptic membrane. It is caused by autoantibodies targeting acetylcholine receptors, muscle-specific kinase, and LRP4. Ocular myasthenia gravis (OMG) is a form of MG characterized by temporary muscle paralysis. Severe MG leads to significant restrictions on daily activities and increased risk of myasthenia crises. Treatment options include intravenous immunoglobulin (IVIG) and plasma exchange (PE). Plasmapheresis (PE) is considered superior due to its quicker response time and higher effectiveness. LPE is a unique medical treatment that combines lymphocyte apheresis with PE techniques. A study involving 236 patients found that LPE can achieve clinical efficacy comparable to or superior to PE while requiring fewer replacements in severe MG cases.